If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
IPO today
Upcoming IPO
AcuityAds Holdings (AT)
Unicycive Therapeutics Inc. (UNCY)
Full Truck Alliance Co. Ltd. (YMM)
First Advantage Corporation (FA)
Sprinklr, Inc. (CXM)
Soulgate Inc. (SSR)
Bright Health Group Inc. (BHG)
Doximity, Inc. (DOCS)
Miromatrix Medical, Inc (MIRO)
Confluent, Inc. (CFLT)
Amtd Digital, Inc. (HKD)
Acurx Pharmaceuticals (ACXP)
Mister Car Wash, Inc. (MCW)
Priced IPO
Century Therapeutics, Inc (IPSC)
Atai Life Sciences B.v. (ATAI)
Femasys (FEMY)
Tremor International Ltd. (TRMR)
Cyteir Therapeutics, Inc. (CYT)
Codex Dna, Inc. (DNAY)
Aihuishou International Co. Ltd. (RERE)
Ambrx Biopharma Inc (AMAM)
iSpecimen (ISPC)
Angel Oak Mortgage, Inc. (AOMR)
Lyell Immunopharma, Inc. (LYEL)
Verve Therapeutics, Inc. (VERV)
Molecular Partners Inc. (MOLN)
Walkme Ltd. (WKME)
Convey Holding Parent, Inc. (CNVY)
Alzamend Neuro (ALZN)
Taskus, Inc. (TASK)
Janux Therapeutics, Inc. (JANX)
Kanzhun Limited (BZ)
Zeta Global Holdings Corp. (ZETA)
More companies

Foghorn Therapeutics Inc. (FHTX)

Sector - Healthcare

Price chart

Return from IPO

Company News

IPO Profile

About company

Company Logo
They are pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, an untapped opportunity for therapeutic intervention. Their proprietary Gene Traffic Control platform gives them an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing them to identify, validate and potentially drug targets within the system. Breakdowns in the chromatin regulatory system are associated with over 50 percent of all cancers. Addressing these breakdowns could potentially provide therapies for over 2.5 million patients. Consequently they are initially focused in oncology. They are developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors, for which they plan to file INDs in the fourth quarter of 2020 and in the first half of 2021, respectively. Their product candidates are in preclinical development, and so they currently do not have any products approved for commercial sale. Their vision is to use their Gene Traffic Control platform to discover and develop drugs in oncology and other therapeutic areas, including virology, autoimmune disease and neurology.
Adrian Gottschalk Allan Reine
Employees Founded
85 2015


Address: 500 Technology Square, Ste 700 Cambridge Ma 02139

Telephone: 617-586-3100

Web page:

IPO information

First Trade Date 10/23/2020
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
Share prices ($)

Shares & Volumes

Shares Initial (MM) 7.5
Shares Revised (MM) 7.5
Expected offer amount (MM) $120
Realized offer amount(MM) $120

Financial Data (last reporting year)

Market Cap (MM) $571.04
Revenues (MM) $0
Net Income (Loss) (MM) $-58.1


What do you think will happen with the FHTX share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
The lead left underwriter: Goldman Sachs

IPOs led by the firm .Pro
Profitability of conducted IPOs  ?  .Pro
1st day change  ?  .Pro
Change for the first 3 months  ?  .Pro
Goldman Sachs/ Morgan Stanley/ Cowen
Wedbush PacGrow

Sector: Healthcare

Tweets about $FHTX

Tweets volume:

RT volume:


Google Trends Stats